KUALA LUMPUR (Dec 6): Mah Sing Group Bhd’s healthcare business unit Mah Sing Healthcare Sdn Bhd has received approval from the US Food and Drug Administration (FDA) to market nitrile examination gloves in the US market.
In a statement on Monday (Dec 6), the group said it received 510(K) clearance from the FDA on Dec 4, and it believes global demand for gloves will continue to rise until 2023.
“With the 501(K) clearance, the recent issuance of a medical device licence from Health Canada and pending the completion of the European Union (EU) Medical Devices Regulation certificate, Mah Sing Healthcare will be able to export medical-grade gloves to a wider range of markets, including major markets such as the US, Canada and Europe.
“This is indeed timely as Mah Sing will complete commissioning all 12 production lines by December and have received numerous customer sales enquiries.
“These new high-speed glove dipping machines can produce 38,000 pieces of gloves per production line per hour, enabling a maximum production capacity of up to 3.68 billion pieces of gloves per annum,” it said.
The group added that it also plans for auto boxing in the near future by collaborating with packing automation specialists.
It will also implement the enterprise resource planning system and advanced supervisory control and data acquisition system.
“Demand for gloves is expected to remain steady due to a structural increase in demand, fears of reinfection, increased health awareness and hygiene compliance requirements for both the healthcare and non-healthcare sectors,” it shared.
At the noon break on Monday, shares in Mah Sing settled 1.5 sen or 2.11% lower at 69.5 sen, giving it a market value of RM1.7 billion.